2-(1-Methylcyclopropyl)benzoic acid | 1379246-31-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(1-Methylcyclopropyl)benzoic acid
• CAS: 1379246-31-7
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.21
• InChiKey: DACFJVCFVNMHEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY<br/>[FR] INHIBITEUR DE BTK AYANT UNE DOUBLE SÉLECTIVITÉ AMÉLIORÉE
  申请人：BEIGENE LTD

  公开号：WO2019034009A1

  公开（公告）日：2019-02-21

  Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases).

  本文披露了一种具有改进的双重选择性的三取代苯基Btk抑制剂，以及用于抑制Btk和治疗与不良Btk活性相关的疾病（Btk相关疾病）的方法和组合物。
• [EN] PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDONE CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2015096651A1

  公开（公告）日：2015-07-02

  Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.

  揭示了式（I）的嘧啶羧酰胺化合物，这些化合物可用作治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的治疗剂，以及其药物组合物和用途。
• PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3087060A1

  公开（公告）日：2016-11-02
• MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
  申请人：RQX Pharmaceuticals, Inc.

  公开号：EP3377473A1

  公开（公告）日：2018-09-26
• [EN] PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS DE PYRIMIDINONE AMIDE EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016183741A1

  公开（公告）日：2016-11-24

  The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction.